Impact of cytomegalovirus infection on biliary disease after liver transplantation - maybe an essential factor

Table 1 Demographics and clinical characteristics comparisons by biliary complications

	Patients with biliary complications (n = 47)	Patients without biliary complications (n = 10)	P value
Age (yr)	33.0 (3.3-51.8)	51.6 (40.6-54.5)	0.021
Sex (M/F)	30/17	10/0	0.059
Primary disease (child)			/
Biliary atresia	11	0
Metabolic disease	6	0
Other	2	0
PELD	16.7 ± 13.5	/	/
Primary disease (adult)
Liver failure	3	0
Decompensated liver cirrhosis	14	10
HCC	9	0
Other	2	0
MELD	14.4 ± 6.3	15 ± 5.5	0.533
Liver transplantation			0.056
LDLT	10	0
DDLT	34	10
Cross-assisted liver transplantation	3	0	0.016
Cold ischemia time (min)	361.9 ± 244.4	582.1 ± 150.9
Warm ischemia time (min)	5 (3-5)	5 (5-7)	0.025
Biliary reconstruction (Duct-to-duct / Roux-en-Y)	23/9	1/9	0.404
Blood CMV status (P/N)	8/39	8/2	0.822
Biliary CMV status (P/N)	22/25	0/10	0.016
Rejection (Yes/No)	29/4	9/1	0.855
HAT (Yes/No)	1/32	0/10	0.578
Biliary drainage			1
PTCD	30	0
ENBD	12	0
T-tube	5	10
Outcome (alive/died)	39/8	10/0	0.365

HCC: Hepatocellular carcinoma; LDLT: Living donor liver transplantation; DDLT: Deceased donor liver transplantation; CMV: Cytomegalovirus; HAT: Hepatic artery thrombosis; PTCD: Percutaneous transhepatic cholangial drainage; ENBD: endoscopic nasobiliary drainage; PELD: Pediatric end-stage liver disease; MELD: Model for end-stage liver disease; M: Male; F: Female; P: Positive; N: Negative.